On Tuesday, Edgewise Therapeutics Inc (NASDAQ: EWTX) opened higher 4.02% from the last session, before settling in for the closing price of $14.18. Price fluctuations for EWTX have ranged from $10.60 to $38.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -49.00%. Company’s average yearly earnings per share was noted -20.23% at the time writing. With a float of $77.10 million, this company’s outstanding shares have now reached $95.21 million.
The extent of productivity of a business whose workforce counts for 110 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Edgewise Therapeutics Inc (EWTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Edgewise Therapeutics Inc is 26.71%, while institutional ownership is 74.67%. The most recent insider transaction that took place on May 02 ’25, was worth 25,520. In this transaction Chief Scientific Officer of this company sold 1,551 shares at a rate of $16.45, taking the stock ownership to the 18,521 shares. Before that another transaction happened on May 02 ’25, when Company’s General Counsel sold 1,930 for $16.45, making the entire transaction worth $31,757. This insider now owns 6,531 shares in total.
Edgewise Therapeutics Inc (EWTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -20.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.15% during the next five years compared to -49.00% drop over the previous five years of trading.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Trading Performance Indicators
Check out the current performance indicators for Edgewise Therapeutics Inc (EWTX). In the past quarter, the stock posted a quick ratio of 20.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.91 in one year’s time.
Technical Analysis of Edgewise Therapeutics Inc (EWTX)
The latest stats from [Edgewise Therapeutics Inc, EWTX] show that its last 5-days average volume of 0.57 million was inferior to 1.4 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 21.69%.
During the past 100 days, Edgewise Therapeutics Inc’s (EWTX) raw stochastic average was set at 20.88%, which indicates a significant decrease from 38.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.19% in the past 14 days, which was lower than the 79.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.65, while its 200-day Moving Average is $24.22. Now, the first resistance to watch is $15.05. This is followed by the second major resistance level at $15.34. The third major resistance level sits at $15.84. If the price goes on to break the first support level at $14.26, it is likely to go to the next support level at $13.76. The third support level lies at $13.47 if the price breaches the second support level.
Edgewise Therapeutics Inc (NASDAQ: EWTX) Key Stats
There are currently 105,200K shares outstanding in the company with a market cap of 1.55 billion. Presently, the company’s annual sales total 0 K according to its annual income of -133,810 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -40,800 K.
